Get Connected:

The ACR/ARHP 2013 Annual Meeting is billed as "the must-attend event for anyone involved in research or delivery of rheumatologic care or services. Innovative sessions, ground breaking scientific abstracts, education developed based on practice gaps, the return of popular session formats, as well as hands-on skill training sessions are just some of the highlights."
ACR/ARHP 2013 Annual Meeting

ACR/ARHP 2013 Annual Meeting | ACR 2013

Conference Coverages

Biologics Beat Triple DMARDs Therapy on Cost, But No Winner in Debate on Efficacy, Safety in RA
Biologics Beat Triple DMARDs Therapy on Cost, But No Winner in Debate on Efficacy, Safety in RA
During their “Great Debate” keynote session of the American College of Rheumatology (ACR) 2013 Annual Meeting in San Diego, CA, two leading rheumatologists took direct aim at each other’s significant clinical trial data to provide rationale for choosing biologics over triple therapy — or vice versa — as the treatment of choice for rheumatoid arthritis (RA).
Meniscus Extrusion Predicts Radiographic Osteoarthritis Change Better Than Cartilage Volume Loss
Although change in knee joint space narrowing depicted on radiographs is considered the gold standard for monitoring osteoarthritis progression and knee cartilage volume loss, the method doesn’t account for extrusion of the medial meniscus, which new research suggests can better predict radiographic osteoarthritis change over time.
Most Rheumatologists Ignore Established Disease Assessment Tools
Although rheumatologists have an array of disease measurement tools to choose from, they generally choose to ignore all of them when they’re assessing rheumatoid arthritis (RA) patients.
5-Year Efficacy Data Shows Golimumab Yields Long-Term RA Improvements
As a follow-up to the initial establishment of Simponi (golimumab)’s safety and efficacy in rheumatoid arthritis (RA), researchers presented final 5-year data evaluating the tumor necrosis factor (TNF) blocker’s effects in RA patients taking methotrexate and those naïve to the biologic agent.
Tocilizumab Treatment Associated with Cardiovascular Improvements in RA Patients
Though rheumatoid arthritis (RA) patients have a significantly higher risk of developing cardiovascular disease (CVD) compared to the general population, results from a pair of studies show that the biologic disease modifier Actemra (tocilizumab) may actually improve the cardiovascular (CV) profiles of RA patients.
Studies Say Vitamin D Deficiency Doesn’t Increase Odds of RA, But May Worsen OA Symptoms
Though previous reports have described a link between vitamin D deficiency and an increased risk of rheumatoid arthritis (RA) development, a trio of studies has now offered clinical support to the contrary belief.
Triple DMARD Treatment More Effective than Monotherapy in New RA Cases
Although methotrexate with or without glucocorticoids (GCs) is commonly used as a first-line treatment in rheumatoid arthritis (RA), study results show that combining the medication with two other traditional disease-modifying anti-rheumatic drugs (DMARDs) produces better outcomes in newly-diagnosed RA patients.

Most Popular

$vacMongoViewPlus$ $vAR$